Investment signals shift toward biochemical monitoring in consumer health, performance and preventative care markets.
Seveno Capital has announced an investment in PointFit, a Hong Kong-based medtech company developing a next-generation wearable patch designed to continuously monitor biomarkers through sweat. The deal marks another step in Seveno’s strategy of backing technologies that sit at the intersection of performance, prevention and longevity – areas where consumer hardware is increasingly converging with clinical-grade ambition.
PointFit’s platform centers on a flexible skin-adherent patch capable of real-time lactate monitoring, with plans to expand into additional sweat-based biomarkers. Positioned initially toward endurance athletes and high-performance users, the company describes a pathway toward broader applications in metabolic health and preventative care.
Longevity.Technology: The wearable market has matured rapidly in form factor yet remains curiously adolescent in physiology – long on steps and heart rate variability, shorter on direct biochemical insight. A sweat-based patch capable of continuously measuring lactate and other biomarkers signals a subtle but important pivot from behavioral proxies toward real-time biology; in longevity terms, that shift matters. Continuous metabolic data, if robustly validated and interpreted within meaningful clinical frameworks, could sharpen how we understand exertion, recovery and early metabolic inflection points – areas that sit squarely at the intersection of performance and healthspan. Of course, the promise of “clinical-grade” data in consumer settings inevitably raises the bar for accuracy, reproducibility and contextual interpretation; more data alone does not equal better decisions. But if platforms like this can translate raw biomarker streams into actionable insight without overwhelming users or drifting into overclaim, they begin to resemble infrastructure rather than accessories – and infrastructure is what longevity, increasingly, requires.
From steps to substrates
For more than a decade, wearable technology has been defined by motion sensors and optical heart rate tracking. These tools have offered valuable behavioral insight, but the are still indirect measures of physiology. Lactate, by contrast, is a metabolic substrate – a molecule with direct relevance to cellular energy dynamics, mitochondrial efficiency and exertional thresholds.
In sports science, lactate has always been the gold standard for defining training zones and pushing performance. But we’ve historically treated it as a snapshot – a single data point captured in a lab. Moving that measurement into a continuous, wearable format changes the game entirely. We’re moving from ‘how did I do?’ to ‘how am I doing right now?’ – tracking recovery debt and mapping metabolic flexibility in real time. In the longevity space, where subtle shifts in metabolic regulation can be the early warning signs of systemic decline years before a diagnosis, these signals are anything but trivial.
Seveno partner Jean-Baptiste Roy described the company’s ambition in practical terms. “We believe continuous biomarker monitoring will become the foundation of personalized performance and preventative health,” he said. “By starting with lactate and expanding into additional analytes, we are building a scalable platform that bridges elite sport and everyday wellbeing.”
Sweat as signal
Sweat is (honestly) an attractive biofluid – accessible, non-invasive and compatible with continuous sampling. It is also biologically complex. Concentrations vary with hydration status, temperature, sweat rate and anatomical location; sensor calibration and signal stability present their own technical challenges. The translation from raw electrochemical readout to clinically interpretable data requires rigorous validation, particularly if claims edge toward medical relevance.
Kenny Oktavius, Co-Founder and CTO of PointFit, emphasized the technical architecture “Our proprietary biosensing platform enables accurate, real-time measurement in a flexible patch format designed for comfort and scalability,” he said. “We are focused on delivering reliable biochemical data that can integrate seamlessly with digital health ecosystems.”
Integration is the operative word. If wearable biomarkers are going to shift from expensive novelties to genuine clinical tools, they can’t exist in a vacuum. They have to feed into interoperable platforms, longitudinal datasets and – eventually – actual clinician workflows. The hardware is just the entry point; it’s the data architecture that determines whether a company has staying power or is just another ‘one-hit wonder’ in a drawer full of discarded tech.
Capital and calibration
Seveno Capital has positioned itself as an investor in technologies that seek to extend healthspan rather than simply treat disease. The firm’s backing of PointFit reflects a view that preventative infrastructure will increasingly depend on continuous, individualized data streams.
Allen Law, Founder of Seveno Capital, framed the rationale in structural terms. “We see a clear transition from episodic healthcare to continuous health monitoring,” he said. “Technologies like PointFit represent the kind of innovation that can help build the infrastructure for long-term health optimization and preventative care.”
The choice of the word ‘infrastructure’ is deliberate. It implies something far more rigorous than a standard wearable – we’re talking about validated metrics, standardized datasets and responsible interpretation. In a market projected to double to $200 billion by 2030, the challenge isn’t going to be a lack of devices; it’s going to be differentiation. Consumers have an insatiable appetite for health data, but their tolerance for ‘black box’ metrics that lack context is wearing thin.
While PointFit is starting with a $15 billion serviceable market in endurance sports, the broader play is much bigger. If you can pair continuous lactate monitoring with electrolytes and hydration markers, the platform stops being a ‘sports patch’ and starts becoming a comprehensive metabolic dashboard. That’s where it moves from an elite performance tool to a foundational piece of the longevity puzzle.
Bridging performance and prevention
The line between winning a race and preventing a chronic disease is becoming increasingly porous. Things like training load and metabolic flexibility aren’t just for athletes; they are direct indicators of cardiometabolic risk and systemic resilience. Wearables that can quantify our biochemical response in real time are effectively pulling double duty – they help you optimize your afternoon run while simultaneously flagging the early deviations from homeostasis that eventually lead to illness. It turns out that the data needed to shave a second off a personal best is the same data needed to add a decade to a healthspan.
At the same time, interpretation remains paramount. A steady stream of numbers does not automatically translate into insight. Algorithms must be trained on representative cohorts; reference ranges must account for sex, age and physiological variability; behavioral recommendations must avoid simplistic thresholds.
This is where investor alignment and scientific rigor intersect. Platforms aspiring to longevity relevance must be built for duration – technically, clinically and commercially.
Biology at the surface
Sweat-based biosensing remains an emerging field, yet it captures a wider movement within health technology: the migration of laboratory metrics to the skin’s surface. As miniaturization improves and sensor chemistry advances, the line between consumer device and clinical monitor becomes less distinct.
Whether PointFit’s approach ultimately reshapes preventative monitoring will depend on validation studies, regulatory pathways and user adoption. The appetite for deeper physiological insight is evident. The discipline to calibrate it correctly will determine its value.
In longevity, data is only as useful as the decisions it informs. Continuous biomarkers offer possibility. Precision will decide the rest.
READ MORE: Allen Law on democratizing healthspan
